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ABSTRACT
Applications of conditional gene expression,
whether for therapeutic or basic research purposes,
are increasingly requiring mammalian gene control
systems that exhibit far tighter control properties.
While numerous approaches have been used to
improve the widely used Tet-regulatory system,
many applications, particularly with respect to the
engineering of synthetic gene networks, will require
a broader range of tightly performing gene control
systems. Here, a generically applicable approach is
described that utilizes intronically encoded siRNA on
the relevant transregulator construct, and siRNA
sequence-specific tags on the reporter construct,
to minimize basal gene activity in the off-state of a
range of common gene control systems. To demon-
strate tight control of residual expression the
approach was successfully used to conditionally
express the toxic proteins RipDD and Linamarase.
The intronic siRNA concept was also extended to
create a new generation of compact, single-vector,
autoinducible siRNA vectors. Finally, using improved
regulation systems a mammalian epigenetic toggle
switch was engineered that exhibited superior
in vitro and in vivo induction characteristics in mice
compared to the equivalent non-intronic system.
INTRODUCTION
An increasing number of therapeutic applications, as well
as basic research pursuits, require the highly controlled
expression of heterologous genes in a mammalian biolo-
gical setting (1). Nowhere is this more evident, than in the
emerging ﬁeld of synthetic biology where the modular
linking of gene control components has already enabled
the creation of many sophisticated functional devices such
as an epigenetic toggle switch (2), hysteretic switch (3),
logic gates (4,5) and time–delay circuits (6,7) amongst
others. However, the creation of further devices, or at
least ones with more stringent properties, is still largely
dependent upon the underlying gene control systems
that are employed. For this reason, the search for new
forms of mammalian gene control, and the step-wise
improvement of existing systems, remains a valuable pur-
suit for the synthetic biology community.
Typical mammalian heterologous transcription control
systems consist of a DNA-binding protein (usually a bac-
terial response regulator) fused to an eukaryotic transcrip-
tional regulator such as the Herpes simplex virus VP16
transactivation domain, or the KRAB (Kruppel-
associated box protein) transsilencing domain (8–10).
Binding of the DNA-binding protein to its cognate
responsive promoter, which is engineered by adjoining
the regulator’s DNA-binding site to an eukaryotic promo-
ter, is dependent upon the presence or absence of an
appropriate eﬀecter molecule (9,11,12). Depending upon
the system and genetic architecture employed, the addition
of an eﬀecter either turns gene expression on or oﬀ (13).
The past decade has seen the continuous emergence of
such gene regulation systems that are responsive to an
ever-increasing range of eﬀecters (14). The earliest systems
were based upon bacterial antibiotic response regulators
inducible by common antibiotics such as tetracycline (9),
streptogramins (11), macrolides (12) and coumermycin/
novobiocin (15). Later systems have been based on res-
ponse regulators sensitive to other signaling molecules,
metabolic compounds and drugs. Non-exhaustive exam-
ples include systems sensitive to the immunosuppressive
drug rapamycin (16), the hormone estrogen (17),
quorum-sensing butyrolactones (18), hypoxia (19,20), the
metabolite L-arginine (21), 6-hydroxy-nicotine (22), gas-
eous acetaldehyde (23) and biotin (vitamin H) (7,24)
amongst others.
Despite the development of many systems, and their
increasing adoption in gene-function studies, an inherent
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residual expression when the systems are in their OFF
conﬁguration. This is due to a combination of the promo-
ter’s basal activity and, or, the random interaction of
binding-incompetent transactivators with their cognate
operators. Compared to equivalent prokaryotic gene con-
trol systems, this leakiness is responsible for the relatively
poor induction factor (ratio of maximal to minimal gene
expression) exhibited by mammalian systems. Apart from
providing a challenge for simple on versus oﬀ gene control
in gene function studies or conditional therapeutic scenar-
ios, this also impacts the functionality of synthetic gene
networks that are based upon these modalities. Given the
primary importance of a strong induction factor for many
network applications, there is consequently a strong need
to develop more tightly regulable gene control systems.
Described here is a new approach that is generically
applicable to a wide variety of existing gene control sys-
tems. It can be used to not only improve the performance
characteristics of transcriptional control systems but also
of synthetic gene networks that are based upon these sys-
tems. Based upon a diﬀerential silencing eﬀect that is
dependent upon the ratio of siRNA to target we have
been able to generically improve the induction proﬁle of
many common gene control systems. These systems were
subsequently used to successfully conditionally express
highly toxic proteins such as the highly eﬃcient apoptosis
inducing death domain of the RIP protein (RipDD)
(25,26), and Cassava (M. esculenta) derived linamarase
which hydrolyses the otherwise innocuous cyanogenic glu-
coside substrate linamarin into glucose, acetone and gas-
eous cyanide thereby mediating eﬃcient cell killing
(27,28). In addition, the same approach of intronically
encoding an siRNA between a heterologous transactiva-
tor, when placed downstream of the transactivator’s
cognate promoter, can also be used to create simple,
single-construct, autoregulated siRNA vectors. Finally, it
was shown that improved gene control systems could be
used to engineer a much improved epigenetic toggle that
exhibited superior induction characteristics in vitro, and
in vivo within mice that had been implanted with encapsu-
lated stable toggle transfected cells.
METHODS
Vector design and construction
All plasmids used in this study as well as their cloning
strategies are listed in Table 1.
Cellculture, transfection and construction ofstable cell lines
Wild-type Chinese hamster ovary cells (CHO-K1, ATCC
CCL 61), together with stable cell line derivatives, were
cultivated and transiently transfected using an optimized
calcium–phosphate-based method as previously described
(29). Human embryonic kidney cells transgenic for the
simian virus 40 large T antigen [HEK293-T (30)], African
green monkey kidney cells (Cos-7, ATCC CRL-1651),
human cervical carcinoma cells (HeLa, ATCC CCL-2)
and mouse ﬁbroblast cells (NIH/3T3, ATCC CRL-1658)
were all cultivated in Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Invitrogen, Basel Switzerland, Cat. No. 52100-
39) supplemented with 10% (v/v) fetal calf serum [Pan
Biotech GmbH, Aidenbach Germany, Cat. No. 3302 Lot
No. P251110] and 1% (v/v) penicillin/streptomycin solu-
tion (Sigma, St Louis USA, Cat. No. P4458). Transient
transfection of HEK293-T, Cos-7 and HeLa cultures was
performed using a standard calcium–phosphate-based
method previously described (31). Transient transfection
of NIH/3T3 was performed using FuGENE6 transfect-
ion reagent (Roche, Mannheim Germany, Cat. No.
11814443001) according to the manufacturer’s instruc-
tions. All cells were grown in a humidiﬁed 5% CO2,3 7 8C
incubator. Unless otherwise indicated, all co-transfections
wereperformedinequimolarratiowithreportergeneactiv-
ity assayed 48h after transfection. Experiments utilizing
the linamarase–linamarin prodrug system were conducted
as previously described using T25 ﬂasks (TPP, Trasadingen
Switzerland) to prevent evaporation of HCN (27).
Linamarin (2-OH-isobutyronitrile-b-D-gluco-pyranoside)
was used at ﬁnal concentration of 750mg/ml.
The monoclonal CHO-K1-derived stable cell line con-
taining pDG168 and pDG161 was created in a two-step
sequential process. First, CHODG168 was created by
co-transfecting pDG168 (PETRON-TAGLuc-Pip-
siRNAGFP-KRAB-IRES-SEAP-pA) and pSV2neo in a
10:1 ratio into CHO-K1 followed by a 2-week cultivation
in G418-containing media (Calbiochem, La Jolla USA,
Cat. No. 345810; ﬁnal concentration 400mg/ml). Integra-
tion of the pDG168 expression cassette and suitability of
erythromycin induction kinetics, in the mixed stable popu-
lation, wastestedbytransientco-transfectionwithpWW43
(PSV40-E-KRAB-pA) followed by erythromycin (EM) dose
proﬁling of SEAP reporter gene expression. The mixed
stable cell line CHODG168 was subsequently co-transfected
with pDG161 (PPIRON-TAGGFP-E-siRNALuc-KRAB-
IRES-pA) and pPUR in a 10:1 ratio followed by a
2-week cultivation in G418 and puromycin-containing
media (Calbiochem, Israel, Cat. No. 540411; ﬁnal concen-
tration 6mg/ml) to yield the mixed double stable cell line
CHODG168/DG161. One hundred and sixty single cell clones
were subsequently isolated, cultivated and screened for
pristinamycin (PI)-repressible and EM-inducible SEAP
expression. Of these, a subset of six clones were further
proﬁled for their ability to maintain diﬀerential expression
upon antibiotic removal. Clone 58 was selected for all
further work and designated as CHOTOGGLE2.
Regulating antibiotics
Pristinamycin (Sanoﬁ-Aventis Inc., Pyostacin, Zurich
Switzerland), erythromycin (Fluka, Buchs Switzerland)
and tetracycline and doxycycline (Sigma Chemicals, St
Louis USA, Cat. Nos. T3383 & D9891) were prepared
as previously described stock solutions (29).
Quantification ofreporter gene expression, cell
viability andapoptosis
Production of human placental-secreted alkaline phospha-
tase (SEAP) was quantiﬁed using a p-nitrophenylphos-
phate-based light absorbance kinetic assay as previously
described (32,33) with results expressed in units per liter
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Plasmid Genotype and/or cloning strategy Reference or source
pBP62 PPIRON-E-KRAB-IRES-pA (2)
pBP139 PETRON1-Pip-KRAB-IRES-SEAP-pA (PETRON1, PhCMV-ETR) (2)
pDG1 PSV40-E-siRNAGFP-VP16-pA (29)
pDG54 PhEF1a-TAGLuc-SEAP-pA. TAGLuc-SEAP created by PCR ampliﬁcation from pSEAP2-Control using
oligos ODG022 (CTTCGACTGAACTAGTGCGGCCGCCCGCTGGAGAGCAACTGCAgaattcac-
caccatgctgc; SpeI site underlined, annealing sequence in lower case, TAGLuc italicised) and
OLM073 (GTACGGAtatcttatcatgtctgctcgaagcgg; EcoRV site underlined, annealing sequence in
lower case), digested with SpeI/EcoRV, and cloned into similarly digested pWW276
This work
pDG97 PSV40-E-siRNAGFP-KRAB-pA (29)
pDG98 PSV40-E-siRNALuc-KRAB-pA. E-siRNALuc fusion with associated splice recognition sequences PCR
ampliﬁed from pWW35 using oligos OWW18 (TAcgaattcccaccatgccccgccccaagctcaa; EcoRI site
underlined, annealing sequence in lower case) and ODG45 (CTGGCGCGCGGGCACCTGTGG
AGAGAAAGGCAAAGTGGATGTCAGTACCGCTGGAGAGCAACTGCAATCGATTGCAGTTG
CTCTCCAGCGGACTTACCTGggctgtacgcggacgc; BssHII site underlined, annealing sequence in
lower case, siRNALuc italicised), digested with EcoRI/BssHII and cloned into similarly digested
pWW43
This work
pDG104 PETRON1-TAGLuc-SEAP-pA. TAGLuc-SEAP excised from pDG54 by SpeI/EcoRV digest and cloned
into SpeI/SmaI digested pWW72 (PETRON1, PhCMV-ETR)
This work
pDG131 PPIRON-E-siRNALuc-KRAB-IRES-pA. E-siRNALuc-KRAB excised from pDG98 by EcoRI/HpaI diges-
tion and cloned into EcoRI/NaeI digested pTRIDENT11
This work
pDG143 PSV40-Pip-siRNAGFP-VP16-pA (29)
pDG153 PSV40-TetR-siRNAGFP-VP16-pA (29)
pDG156 PhCMV -1-E-VP16-pA. PhCMV -1 excised from pMF111 by SspI/EcoRI digestion and cloned into similarly
digested pWW35
This work
pDG159 PhCMV -1-E-siRNAGFP-VP16-pA. PhCMV -1 excised from pMF111 by SspI/EcoRI digestion and cloned
into similarly digested pDG1
This work
pDG160 PETRON1-TAGLuc-Pip-pA. PETRON1-TAGLuc created by PCR-ampliﬁcation from pBP139 using oligos
ODG053 (cgacacggaaatgttg, entire sequence annealing) and ODG55
(TCCGGAATTCTGCAGTTGCTCTCCAGCGGAGAtctgcaggatatccctaaatg; EcoRI site underlined,
annealing sequence in lower case, TAGLuc italicised), digested with SspI/EcoRI, and cloned into
similarly digested pWW87 (PETRON1, PhCMV-ETR)
This work
pDG161 PPIRON-TAGGFP-E-siRNALuc-KRAB-IRES-pA. PPIRON-TAGGFP created by PCR-ampliﬁcation from
pTRIDENT11 using oligos ODG53 (cgacacggaaatgttg, entire sequence annealing) and ODG54
(TCCGGAATTCGTAGTTGTACTCCAGCTTGTGAGATCtcgaaatagcgctgtacag; EcoRI site under-
lined, annealing sequence in lower case, TAGGFP italicised), digested with SspI/EcoRI and cloned
into similarly digested pDG131
This work
pDG163 PSV40-Pip-siRNAGFP-KRAB-IRES-pA. siRNAGFP-KRAB fusion with associated splice recognition
sequences PCR-ampliﬁed from pWW43 using oligos ODG56 (CTGGCGCGCCAGGTAAGTCA
CAAGCTGGAGTACAACTACATCGATGTAGTTGTACTCCAGCTTGTGTACTGACATCCACTT-
TGCCTTTCTCTCCACAGGTGcgccagatccaaaaaag; BssHII site underlined, annealing sequence in
lower case, siRNAGFP italicised) and ODG57 (atcgaagcttggatccttac; HindIII site underlined, entire
sequence annealing), digested with BssHII/HindIII and cloned into similarly digested pMF167
This work
pDG164 PETR1-E-VP16-pA. PETR1 excised from pWW37 by SspI/EcoRI digestion and cloned into similarly
digested pWW35 (PETR1, ETR-PhCMVmin)
This work
pDG165 PETR1-E-siRNAGFP-VP16-pA. PETR1 excised from pWW37 by SspI/EcoRI digestion and cloned into
similarly digested pDG1 (PETR1, ETR-PhCMVmin)
This work
pDG167 PETRON1-TAGLuc-Pip-siRNAGFP-KRAB-IRES-pA. Pip-siRNAGFP-KRAB-IRES excised from
pDG163 by EcoRI/KpnI digestion and cloned into similarly digested pDG160 (PETRON1, PhCMV-
ETR)
This work
pDG168 PETRON1-TAGLuc-Pip-siRNAGFP-KRAB-IRES-SEAP-pA. SEAP excised from pLM177 by SpeI/MluI
digestion and cloned into similarly digested pDG167 (PETRON1, PhCMV-ETR)
This work
pDG178 PhCMV -1-TetR-VP16-pA. TetR excised from pSAM200 by EcoRI/BssHII digestion and cloned into
similarly digested pDG156
This work
pDG179 PhCMV -1-TetR-siRNAGFP-VP16-pA. TetR excised from pSAM200 by EcoRI/BssHII digestion and
cloned into similarly digested pDG159
This work
pDG181 PETRON1-GFP-pA. GFP was PCR-ampliﬁed from pLEGFP-N1 using oligos ODG62 (GATCGC
TAGCTTAAGCTTGGTACCGGATCCgccaccatggtgagc; NheI site underlined, annealing sequence
in lower case) and ODG63 (CTCGAGCGGCCGCCACTGTGCTGGATATCgctttacttgtacagctcgtcc;
NotI site underlined, annealing sequence in lower case), digested with NheI/NotI and cloned into
SpeI/NotI digested pWW72 (PETRON1, PhCMV-ETR)
This work
pDG182 PETR1-GFP-pA. GFP excised from pDG181 by EcoRI/NotI digestion and cloned into similarly digested
pDG183 (PETR1, ETR-PhCMVmin)
This work
pDG183 PETR1-TAGGFP-SEAP-pA. TAGGFP-SEAP excised from pLM65 by SpeI/NotI digest and cloned into
similarly digested pWW125 (PETR1, ETR-PhCMVmin)
This work
pDG191 PETRON1-TAGGFP-SEAP-pA. TAGGFP-SEAP excised from pLM65 by SpeI/NotI digest and cloned
into similarly digested pWW72 (PETRON1, PhCMV-ETR)
This work
pDG210 PSV40-rTetR-siRNAGFP-VP16-pA. rTetR excised from pTET-ON by EcoRI/BssHII digestion and
cloned into similarly digested pDG1
This work
(continued)
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Plasmid Genotype and/or cloning strategy Reference or source
pDG211 PhCMV -1-TAGGFP-SEAP-pA. PhCMV -1 excised from pMF111 by SspI/XbaI digestion and cloned into
SspI/SpeI digested pDG183
This work
pDG213 PPIR-TAGGFP-SEAP-pA. PPIR excised from pMF189 by SspI/SpeI digestion and cloned into similarly
prepared pDG183
This work
pDG276 PETR2-TAGGFP-SEAP-pA. Phsp70min and TAGGFP excised from pDG213 by SbfI/BssHII digestion and
cloned into similarly prepared pDG183 (PETR2, ETR-Phsp70min)
This work
pDG280 PETRON2-TAGGFP-SEAP-pA. ETR operator module and TAGGFP excised from pDG191 by HindIII/
NdeI digestion and cloned into similarly prepared pLM189 (PETRON2, PPGK-ETR)
This work
pDG284 PETR3-TAGGFP-SEAP-pA. PSV40min PCR ampliﬁed from pSEAP2-Control using primers ODG092
(ACCGTACAAGGAGCCTGCAGgcgatctgcatctcaattagtc; SbfI site underlined, annealing sequence
in lower case) and ODG093 (ggaggcctaggcttttgcaaaCTAGTCACATGCTGG; SpeI site underlined,
annealing sequence in lower case), digested with SbfI/SpeI and cloned into similarly prepared
pDG183 (PETR3, ETR-PSV40min)
This work
pDG286 PETR1-TAGGFP-Lis-pA. PETR1 and TAGGFP PCR ampliﬁed from pDG183 using primers ODG085
(ggaaatgttgaatactcatactcttcc, entire sequence annealing) and ODG094 (cacaagctggagtacaactac
GCGCGCCCACCA, BssHII site underlined, annealing sequence in lower case), digested with
AatII/BssHII and cloned into similarly prepared pWW315 (PETR1, ETR-PhCMVmin)
This work
pDG287 PETRON1-TAGGFP-Lis-pA. PETRON1 and TAGGFP excised from pDG290 by AatII/BssHII digestion
and cloned into similarly prepared pWW315 (PETRON1, PhCMV-ETR)
This work
pDG289 PETR1-TAGGFP-RipDD-pA. PETR1 and TAGGFP PCR ampliﬁed from pDG183 using primers ODG085
and ODG094 (see above), digested with AatII/BssHII and cloned into similarly prepared pWW326
(PETR1, ETR-PhCMVmin)
This work
pDG290 PETRON1-TAGGFP-RipDD-pA. PETRON1 and TAGGFP PCR ampliﬁed from pDG191 using primers
ODG085 and ODG094 (see above), digested with AatII/BssHII and cloned into similarly prepared
pWW326 (PETRON1, PhCMV-ETR)
This work
pLEGFP-N1 PhCMV-GFP-pA Clontech
pLM65 PhEF1a-TAGGFP-SEAP-pA (35)
pLM177 PhEF1a-SEAP-pA (35)
pLM189 PNICON4-SEAP-pA (PNICON3, PPGK-ONIC) (49)
pmCMVmpA mPhCMV-mpA (34)
pmCMVsiGFPmpA mPhCMV-siRNAGFP-mpA (34)
pMF111 PhCMV -1-SEAP-pA (61)
pMF167 PSV40-Pip-VP16-pA (62)
pMF189 PPIR-MCS-pA (36)
pPUR PSV40-Puro
r-pA Clontech
pSAM200 PSV40-TetR-VP16-pA (60)
pSEAP2-Control PSV40min-SEAP-pA-ESV40 Clontech
pSV2neo PSV40-Neo
r-pA Clontech
pTet-ON PhCMV-rTetR-VP16-pA Clontech
pTRIDENT11 PPIRON-MCS-IRES-MCS-IRES-MCS-pA (63)
pWW35 PSV40-E-VP16-pA (12)
pWW37 PETR-SEAP-pA (PETR1, ETR-PhCMVmin) (12)
pWW43 PSV40-E-KRAB-pA (12)
pWW56 PETRON1-SEAP-pA (PETRON1, PhCMV-ETR) (12)
pWW72 PETRON-MCS-pA (PETR1, ETR-PhCMVmin) (36)
pWW87 PETRON-Pip-pA (PETR1, ETR-PhCMVmin) (2)
pWW125 PETR-MCS-pA (PETR1, ETR-PhCMVmin) (36)
pWW276 PhEF1a-VEGF-pA (64)
pWW315 PhEF1a-Lis-pA (27)
pWW326 PhEF1a-RipDD-pA (27)
E, E. coli-derived repressor of the macrolide resistance gene mphA; E-KRAB, macrolide-dependent transsilencer; ESV40, SV40 enhancer; ETR,
operator sequence speciﬁc for E binding; E-VP16, macrolide-dependent transactivator; GFP, enhanced green ﬂuorescence protein; IRES, internal
ribosome entry site; KRAB, human kox-1 gene transcriptional silencer; Lis, Cassava (M. esculenta) linamarase; Luc, ﬁreﬂy luciferase; MCS, multiple
cloning site; mPhCMV, modiﬁed PhCMV promoter; mpA, synthetic minimal pA; Neo
r, neomycin (G418) resistance conferring gene; pA, virus-derived
polyadenylation site; PETR1-3, macrolide-responsive OFF-type promoters containing a single ETR module upstream of either PhCMVmin,P hsp70min or
PSV40min respectively; PETRON1-2, macrolide-responsive ON-type promoters containing eight ETR modules downstream of either PSV40 or PPGK,
respectively; PPGK, constitutive murine phosphoglycerate kinase promoter; PhCMV, constitutive human cytomegalovirus immediate early promoter;
PhCMV -1, tetracycline responsive promoter containing seven TetO modules upstream of PhCMVmin;P hCMVmin, minimal PhCMV;P hEF1a, constitutive
human elongation factor 1a promoter; Phsp70, constitutive Drosophila heat-shock gene hsp70 promoter; Phsp70min, minimal Phsp70; Pip, S. coelicolor-
derived repressor of the streptogramin resistance operon; PIR, operator sequence speciﬁc for Pip binding; PPIR, streptogramin-responsive OFF-type
promoter containing a single PIR module upstream of Phsp70min;P PIRON, streptrogramin-responsive ON-type promoter containing three PIR
modules downstream of PSV40;P SV40, constitutive simian-40 virus derived promoter with ESV40;P SV40min, minimal PSV40 promoter without ESV40;
Puro
r, puromycin resistance conferring gene; RipDD, human RIP death domain; rTetR, mutated TetR exhibiting reverse binding characteristics to
tetracycline; SEAP, human placental secreted alkaline phosphatase; siRNA, short interfering RNA (subscript denotes speciﬁcity); TAG, siRNA
speciﬁc target sequence (subscript denotes speciﬁcity); TetO, operator sequence speciﬁc for TetR binding; TetR, E. coli-derived repressor of the TN10
tetracycline resistance operon; VP16, Herpes simplex virus-derived transcriptional activator.
e101 Nucleic Acids Research, 2008, Vol. 36, No. 16 PAGE4 OF16(U/l) or, where relevant, relative to isogenic control vec-
tors (rU/l). Expression proﬁling of GFP was performed by
FACS analysis of harvested cells using a Cytomics FC500
ﬂow cytometer with Beckman CFP analysis software
(Beckman Coulter, CA, USA) set for 488nm excitation
and recording at 525nm, with results expressed in either
ﬂuorescence units (FU) or relative to isogenic control vec-
tors (%).
The total cell number and viability of harvested cells,
expressed as a percentage of living cells (%), was deter-
mined using a Casy1 cell counter (Schaerfe System,
Reutlingen, Germany).Apoptosis proﬁlesweredetermined
after staining of harvested cells using an annexin V-FITC/
7-AAD apoptosis assay kit (Beckman Coulter, Marseille
France, Cat. No. PN IM3614) used according to the man-
ufacturer’s protocol. Dye incorporation and quantiﬁcation
of apoptotic cells, expressed as the percentage of cells posi-
tive for either or both of annexin V-FITC or 7-AAD, was
also performed using the above ﬂow cytometer and analy-
tical software which was set for 488nm excitation and
recording at 525nm (FITC) and 655nm (7-AAD).
Encapsulation and invivo methods
CHOTOGGLE2 cells were encapsulated in 400mm alginate-
poly-(L-lysine)-alginate beads (alginate-PLL-alginate; 200
cells per capsule) using an Inotech Encapsulator Research
IER-20 (Inotech Encapsulation AG, Dottikon,
Switzerland) according to the manufacturer’s instructions
and the following speciﬁc parameters: 0.2mm nozzle, 405
unit ﬂow rate using 20ml syringe, 1088Hz nozzle vibra-
tion frequency and 900V for bead dispersion. Seven hun-
dred microliters MOPS-buﬀered physiological salt
solution (Inotech Encapsulation AG, Dottikon,
Switzerland) containing 2 10
6 encapsulated cells were
injected intraperitoneally into female OF1 mice (oncins
france souche 1; Iﬀa-Credo, Lyon France). Control mice
were injected with encapsulated wild-type CHO-K1 cells.
Starting 1h after injection and continuing daily where
required, mice were administered either pristinamycin or
erythromycin at ﬁnal doses of 50mg/kg. Both pristinamy-
cin and erythromycin were formulated for in vivo admin-
istration by dilution of stock solutions to appropriate
concentrations using a 0.9% (w/v) NaCl solution contain-
ing 5% (v/v) ethanol. At required time points, blood was
collected retro-orbitally and serum obtained using micro-
tainer SST tubes (Becton Dickinson, Plymouth, UK). All
experiments involving mice were approved by the French
Ministry of Agriculture and Fishery (Paris France) and
performed by M.D-E at the Institute Universitaire de
Technologie (IUTA), F-69200 Villeurbanne Cedex,
France.
RESULTS
Differential siRNA silencing improves dynamic rangeof
transgenecontrol systems
The extent of siRNA-mediated gene-silencing during tran-
sient transfection is inﬂuenced, amongst other factors, by
the relative concentration of siRNA to target. This was
demonstrated by testing the silencing eﬃciency of a
common GFP-speciﬁc siRNA (34), constitutively
expressed from its own dedicated promoter
(pmCMVsiGFPmpA; mPhCMV-siRNAGFP-mpA), at vary-
ing siRNA to target (pLEGFP-N1, PhCMV-GFP-pA)
ratios in CHO cells (Figure 1). At siRNA to target
ratios lower than 1, silencing of GFP was undetectable
relative to isogenic control transfections (pmCMVmpA;
mPhCMV-mpA). At a 1 to 1 ratio, silencing of  50%
was observed. Increasing ratios thereafter resulted in
higher silencing eﬃciencies with maximal silencing in the
range of 80–90% occurring only at ratios greater than 10.
By targeting an siRNA against a reporter gene, itself
placed under expression control of a transcription control
system, it was speculated that the observed diﬀerential
silencing eﬃciency of siRNA could be used to improve
the induction ratio of a transcription control system.
Assuming siRNA is constitutively produced at a constant
level, the relative level of siRNA to reporter mRNA
should be much higher in the OFF conﬁguration than in
the ON conﬁguration; thus leading to disproportionately
higher silencing of residual OFF expression than maximal
ON expression. By expressing a functional siRNA as a
synthetic intron between the erythromycin (EM)-inducible
DNA-binding protein and the relevant transcriptional reg-
ulator we sought to test the hypothesis that diﬀerential
siRNA silencing could be used to improve the induction
characteristics of the EM-responsive (E.REX) EOFF and
EON systems (12,29) (Figure 2). Intronically encoded
GFP-speciﬁc siRNA (siRNAGFP), placed within the ET1
(pDG1; PSV40-E-siRNAGFP-VP16-pA) and ET4 (pDG97;
PSV40-E-siRNAGFP-KRAB-pA) transregulators were used
to directly target GFP which itself was placed under
expression control of either ET1-(pDG182; PETR1-GFP-
pA) or ET4-(pDG181; PETRON1-GFP-pA) responsive
promoters, respectively. Relative to the native transregu-
lators ET1 (pWW35; PSV40-E-VP16-pA) and ET4
(pWW43; PSV40-E-KRAB-pA), diﬀerential siRNA-
mediated silencing between the ON and OFF
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Figure 1. Impact of siRNA to gene target ratio on RNAi-mediated
gene silencing. GFP expression of CHO-K1 cells after co-transfection
with varying ratios of target GFP (pLEGFP-N1; PhCMV-GFP-pA) and
a siRNA directed against GFP (pmCMVsiGFP-mpA; mPhCMV-
siRNAGFP-mpA). For each ratio, GFP production was assessed relative
to equivalent co-transfections of pLEGFP-N1 and an isogenic (non-
siRNA containing) control (pmCMVmpA; mPhCMV-mpA).
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of the EOFF and EON systems from 10- to 39-fold, and
19- to 60-fold, which represents a 4- and 3-fold incremen-
tal improvement, respectively.
The system thus described relies upon a speciﬁc siRNA
targeting a desired reporter gene (in this case GFP).
Further application to other reporter genes would require
de novo design of a reporter gene speciﬁc siRNA in each
case. To circumvent this issue, and make the system gen-
erically applicable to any reporter gene, the siRNAGFP
target sequence (TAG) was incorporated into the 50
untranslated region of another reporter gene, namely
SEAP, thereby rendering it capable of siRNAGFP
mediated silencing (35) (Figure 3). The performance of
the resulting system (For EOFF we used pDG183; PETR1-
TAGGFP-SEAP-pA, and for EON pDG191; PETRON1-
TAGGFP-SEAP-pA) with respect to diﬀerential silencing,
strong reduction of basal expression, and improvement in
induction characteristics (4-fold for ET1 and 3-fold for
ET4) was consistent with the improvement observed in
the directly targeted reporter system.
To ascertain whether a diﬀerent intronic siRNA/TAG
combination would have the same eﬀect, an EON system
utilizing an intronic siRNA against luciferase (pDG98;
PSV40-E-siRNALuc-KRAB-pA) with a corresponding
luciferase TAG on the reporter construct was also tested
(pDG104; PETRON1-TAGLuc-SEAP-pA). In direct com-
parisons of knockdown eﬃciency, siRNALuc has been
more eﬃcient than siRNAGFP (93 versus 80%) (29).
When siRNALuc was used within the EON system in tran-
sient co-transfections of CHO-K1, maximal and minimal
SEAP reporter expression in the presence and absence, res-
pectively,oferythromycinwere6.4U/l( 0.4)and0.06U/l
( 0.02). In comparison to the native EON system this cor-
responded to silencing ratios of 68 and 93%, respectively,
and an overall induction ratio of 99-fold which was
approximately 5-fold higher than the native EON system.
Despite signiﬁcantly reducing maximal expression (i.e.
68%), this showed that the use of a more eﬃcient siRNA
could also be used to improve induction characteristics
because of the higher reduction observed in minimal
expression (i.e. 93%). This suggests that diﬀerential
siRNA-mediated silencing is not dependent upon a partic-
ular siRNA per se, but rather the ratio of siRNA to target.
To further investigate the impact of diﬀerent siRNAs
upon system characteristics, erythromycin dose response
proﬁles for the native, and intronic GFP- and intronic
Luc-containing siRNA EON systems were compared
(Figure 4). Apart from the change in induction character-
istics described earlier, a tightening of the inducer
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Figure 2. Schematic representation and comparison of E.REX (EOFF and EON) induction characteristics following inclusion within ET1 (pWW35;
PSV40-E-VP16-pA) and ET4 (pWW43; PSV40-E-KRAB-pA) of an intronically encoded siRNA (pDG1; PSV40-E-siRNAGFP-VP16-pA and pDG97;
PSV40-E-siRNAGFP-KRAB-pA, respectively) directed against a GFP reporter gene whose expression was placed under control of the relevant ET1 or
ET4 responsive promoter (pDG182; PETR1-GFP-pA and pDG181; PETRON1-GFP-pA, respectively). In each case erythromycin (EM) dose proﬁles
for either the native or intronic siRNA-containing transcriptional regulator ET1 (A) or ET4 (B) were determined in CHO-KI following
co-transfection with the relevant responsive GFP reporter construct. Also shown are expression levels resulting from transfection with just the
relevant reporter construct.
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both intronic siRNA containing systems. This was great-
est for the intronic siRNALuc system where the erythro-
mycin concentration at which the system began to switch
‘ON’ increased from 10 to  100ng/ml. For both systems
there were minimal changes to the concentration at which
the system was fully induced ( 1000ng/ml). Referring
back to Figure 1 these results are consistent with the
impact of the siRNA to target ratio upon gene silencing.
For a relatively eﬃcient siRNA such as siRNALuc, max-
imum silencing occurs at a relatively lower siRNA to
target ratio. Hence, maximal silencing does not require
ET4 to be entirely shut-oﬀ which accordingly shifts the
beginning of the inducer window to the right. However,
with respect to the end of the end of the induction
window, there is no equivalent shift as once ET4 is com-
pletely active there is no further change in siRNA-
mediated silencing levels. Taken together this results in
an overall compression of the inducer window.
To test the applicability of the approach to other mam-
malian systems, the performance of the native and intronic
siRNA containing versions of the EOFF and EON control
systems were also determined in several other mammalian
cell types; in particular the human cell lines HEK293-T
and HeLa, the monkey cell line Cos-7, and the mouse cell
line NIH/3T3 (Table 2). In each respective case, the
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Figure 3. Schematic illustration and comparison of induction performance of EOFF and EON systems containing intronic siRNA against a target that was
placedimmediately upstreamofagenericreportergene.NativeandintronicsiRNA-containingerythromycin(EM)doseproﬁlesfor(A)E OFFand(B)E ON
systems were determined after co-transfection of CHO-K1 with the relevant transcriptional regulator (pWW35—native ET1; PSV40-E-VP16-pA, pDG1—
ET1 containing intronically encoded siRNA against GFP; PSV40-E-siRNAGFP-VP16-pA, pWW43—native ET4; PSV40-E-KRAB-pA or pDG97—ET4
containing intronically encoded siRNA against GFP, PSV40-E-siRNAGFP-KRAB-pA) and the corresponding ET1/ET4 responsive SEAP reporter con-
struct containing the siRNA target sequence (TAGGFP) immediately upstream of the SEAP reporter gene (EOFF pDG183; PETR1-TAGGFP-SEAP-pA and
EON pDG191; PETRON1-TAGGFP-SEAP-pA). Also shown are expression levels resulting from transfection with just the relevant reporter construct.
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Figure 4. Comparison of erythromycin (EM) dose response proﬁles for
native and two diﬀerent intronic siRNA-containing EON systems.
Reporter gene expression levels were determined after co-transfection
of CHO-K1 with either the native system (pWW43; PSV40-E-KRAB-
pA, and pWW56: PETRON1-SEAP-pA), an intronic siRNA system
utilizing intronic siRNAGFP and TAGGFP upstream of the reporter
(Intronic GFP: pDG97; PSV40-E-siRNAGFP-KRAB-pA, and pDG191:
PETRON1-TAGGFP-SEAP-pA), or an intronic siRNA system utilizing
intronic siRNALuc (luciferase) and TAGLuc upstream of the reporter
(Intronic Luc: pDG98; PSV40-E-siRNALuc-KRAB-pA, and pDG104:
PETRON1-TAGLuc-SEAP-pA). For each respective system, SEAP
reporter expression levels are stated relative (%) to the maximal gene
expression level observed for that system.
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induction performance with the extent of residual expres-
sion in the OFF conﬁguration generally approaching the
detection limit of the reporter gene assay. This conﬁrmed
that diﬀerential silencing between ON and OFF conﬁgura-
tions occurred irrespective of whether the system was
placed in a highly expressing cell line (e.g. HEK293-T or
Cos-7) or a much lower expressing and tightly regulating
cell line such as NIH/3T3. Indeed for the latter, the reduc-
tion in residual expression in the OFF conﬁguration to the
detection limit of the reporter assay (6 mU/l) for SEAP
(36) resulted in an almost inﬁnite induction ratio (i.e.
>2000-fold). Signiﬁcantly, for the EOFF system the
strong siRNA-mediated silencing of leaky expression in
the OFF conﬁguration reduced expression levels to well
below that of equivalent transfections with just the repor-
ter gene alone. This was never achieved in the OFF con-
ﬁguration with the native EOFF system.
Given the inﬂuence of diﬀerent underlying promoters on
gene control system characteristics, the minimal PhCMVmin
and constitutive PSV40 promoters of the standard EOFF
(pDG183) and EON (pDG191) -TAGGFP-SEAP-pA repor-
ter constructs, were substituted with Drosophila heat shock
hsp70 (pDG276; PETR2-, ETR-Phsp70min ) and simian-40
virus derived (pDG284; PETR3, ETR-PSV40min ) minimal
promoters, and the murine phosphoglycerate kinase
(pDG280; PETRON2-, PPGKETR-) constitutive promoter,
respectively. A comparison of the performance of these
systems using both native and intronic siRNA containing
transregulators demonstrated that diﬀerential silencing
between ON and OFF conﬁgurations, and resulting
improved induction performance, existed for the intronic
siRNA systems irrespective of the underlying promoter
(Table 3). This occurred when the underlying promoter
was weaker (e.g. Phsp70min for EOFF) or stronger (e.g.
PSV40min for EOFF or PPGK for EON) with the overall
improvement ranging from 3- to 11-fold.
Exploiting thestandard architecture andmodularnature
of many gene control systems, the generic intronic siRNA
concept was extended to improve the induction character-
istics of several other common transcription control sys-
tems. Therefore, intronically encoded siRNAGFP was
placed within the tetracycline (Tet)-dependent transactiva-
tor tTA (pDG153; PSV40-TetR-siRNAGFP-VP16-pA), the
reverse doxycycline (Dox)-dependent transactivator rtTA
(pDG210; PSV40-rTetR-siRNAGFP-VP16-pA), and the
pristinamycin (PI)-dependent transactivator PIT
(pDG143; PSV40-Pip-siRNAGFP-VP16-pA). Using appro-
priate reporter constructs containing a TAGGFP
(pDG211; PhCMV
 
 1-TAGGFP-SEAP-pA, pDG213; and
PPIR-TAGGFP-SEAP-pA, respectively) and relative to
native transactivators (pSAM200; PSV40-TetR-VP16-pA,
pTET-ON; PSV40-rTetR-VP16-pA, pMF167 and PSV40-
Pip-VP16-pA, respectively), all systems exhibited between
a 3- and 5-fold improvement in regulation performance
(Figure 5).
Improved transgeneexpression allows tight conditional
expression of toxic gene products
Irrespective of the cell type, underlying promoter or tran-
scription control system used, the generally observed 3- to
Table 2. Comparison of induction performance of native versus intronic siRNA containing EOFF and EON systems in diﬀerent mammalian cell types
Cell type
HEK293-T Cos-7 HeLa NIH/3T3
EOFF system
Reporter alone 28.2 0.4 3.7 0.4 0.3 0.0 0.04 0.01
Native ET1 ( EM) 860.5 33.4 653.4 48.8 225.3 10.8 20.66 2.34
Native ET1 (+EM) 29.2 1.9 7.6 0.8 0.9 0.1 0.10 0.04
Intronic ET1 ( EM) 720.6 20.6 633.9 64.2 109.5 6.4 11.59 2.20
Intronic ET1 (+EM) 5.1 0.6 1.9 0.1 0.1 0.1 0.01 0.01
Induction factor ( )
Native ET1 29.5 86.4 240.2 208.9
Intronic ET1 140.5 333.8 1963.0 2074.5
Change 4.8 3.9 8.2 9.9
EON system
Reporter alone 5.28 0.91 14.68 0.64 2.07 0.52 3.29 0.06
Native ET4 ( EM) 0.92 0.08 1.56 0.11 0.16 0.00 0.23 0.17
Native ET4 (+EM) 5.32 0.77 13.81 1.64 2.26 0.33 1.59 0.42
Intronic ET4 ( EM) 0.17 0.27 0.40 0.05 0.02 0.14 0.03 0.02
Intronic ET4 (+EM) 2.44 0.32 12.00 1.18 0.86 0.13 0.94 0.17
Induction factor (x)
Native ET4 5.8 8.9 14.3 7.0
Intronic ET4 14.5 30.2 39.9 29.9
Change 2.5 3.4 2.8 4.3
ET1 or ET4 responsive SEAP reporter constructs containing the siRNA target sequence (TAGGFP) immediately upstream of the SEAP reporter gene
(EOFF pDG183; PETR1-TAGGFP-SEAP-pA and EON pDG191; PETRON1-TAGGFP-SEAP-pA) were transfected alone or together with either native
(ET1, pWW35; PSV40-E-VP16-pA and ET4, pWW43; PSV40-E-KRAB-pA) or intronic siRNAGFP containing (ET1, pDG1; PSV40-E-siRNAGFP-VP16-
pA and ET4, pDG97; PSV40-E-siRNAGFP-KRAB-pA) transregulators into diﬀerent cell types, and scored for SEAP production (U/l) in the presence
or absence of 5mg/ml erythromycin (EM). The resulting induction factor between OFF and ON expression levels is shown in each case.
e101 Nucleic Acids Research, 2008, Vol. 36, No. 16 PAGE8 OF1610-fold improvement in induction characteristics of the
intronic siRNA approach was suﬃcient to improve resi-
dual leakiness to less than, or close to, 1% of maximal
gene expression. To determine whether this improvement
in reducing basal leakiness was of signiﬁcance we sought
to compare intronic siRNA mediated versus native tran-
scription control of two toxic gene products. In the ﬁrst,
the highly toxic RIP death domain (RipDD) (25,26) was
cloned immediately downstream of TAGGFP containing
EOFF and EON responsive promoters (for EOFF we used
pDG289; PETR1-TAGGFP-RipDD-pA and for EON
pDG290; PETRON1-TAGGFP-RipDD-pA), and expres-
sion of RipDD in HeLa controlled with either native or
intronic siRNA containing ET1 (pWW35 or pDG1) or
Table 3. Comparison of induction performance within CHO-K1 of
native versus intronic siRNA containing EOFF and EON systems utiliz-
ing diﬀerent minimal and constitutive promoters adjacent to the rele-
vant ETR operator module(s)
Minimal promoter following single
ETR operator
PhCMVmin Phsp70min PSV40min
EOFF system
Reporter alone 0.38 0.05 0.12 0.01 1.98 0.10
Native ET1 ( EM) 39.63 3.16 6.59 3.25 80.48 7.97
Native ET1 (+EM) 1.61 0.29 0.78 0.16 6.36 0.47
Intronic ET1 ( EM) 21.24 0.14 2.53 0.07 66.05 0.09
Intronic ET1 (+EM) 0.19 0.04 0.03 0.00 0.84 0.04
Induction factor ( )
Native ET1 24.7 8.4 12.6
Intronic ET1 109.8 93.8 78.2
Change 4.4 11.2 6.2
Constitutive promoter preceding octet
ETR operator
PSV40 PPGK
EON System
Reporter alone 31.48 1.16 87.48 15.68
Native ET4 ( EM) 0.98 0.10 3.16 0.66
Native ET4 (+EM) 21.64 2.90 51.91 21.37
Intronic ET4 ( EM) 0.13 0.04 0.15 0.03
Intronic ET4 (+EM) 9.09 0.63 23.06 0.66
Induction factor ( )
Native ET4 22.0 16.4
Intronic ET4 71.0 158.9
Change 3.2 9.7
EOFF reporter constructs containing either the PhCMVmin (pDG183;
PETR1-, ETR-PhCMVmin-), Phsp70min (pDG276; PETR2-, ETR-Phsp70min ),
or PSV40min (pDG284; PETR3-, ETR-PSV40min-) minimal promoters, and
EON reporterconstructs containingeither the PSV40(pDG191; PETRON1-,
PSV40-ETR-) or PPGK (pDG280; PETRON2-, PPGK-ETR-) constitutive
promoters, which drive transcription of a siRNA target sequence
(TAGGFP) immediately upstream of a SEAP reporter gene, were trans-
fected aloneortogether withnative (ET1,pWW35; PSV40-E-VP16-pA and
ET4, pWW43; PSV40-E-KRAB-pA) or intronic siRNAGFP containing
(ET1, pDG1; PSV40-E-siRNAGFP-VP16-pA and ET4, pDG97; PSV40-
E-siRNAGFP-KRAB-pA) transregulators, and scored for SEAP
production (U/l) in the presence or absence of 5mg/ml erythromycin
(EM). The resulting induction factor between OFF and ON expression
levels for each system is shown in each case.
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Figure 5. Extension of intronic siRNA/TAG concept to other gene reg-
ulation systems in CHO-K1. For each system the induction performance
of the native transactivator was compared against the same transactivator
containing an intronically encoded siRNAGFP, the target (TAGGFP)o f
which was incorporated immediately upstream of a SEAP reporter gene
that was placed under control of the requisite transactivator responsive
promoter. (A) TetOFF tetracycline (Tet) dose response in which either
native tTA (pSAM200; PSV40-TetR-VP16-pA) or intronic siRNAGFP con-
taining tTA (pDG153; PSV40-TetR-siRNAGFP-VP16-pA) was co-trans-
fected with pDG211 (PhCMV
 
 1-TAGGFP-SEAP-pA). (B) TetON
doxycycline (Dox) dose response in which either native rtTA (pTET-
ON; PSV40-rTetR-VP16-pA) or intronic siRNAGFP containing rtTA
(pDG210; PSV40-rTetR-siRNAGFP-VP16-pA) was co-transfected with
pDG211. (C)P I OFF pristinamycin (PI) dose response in which either
nativePIT(pMF167;PSV40-Pip-VP16-pA)orintronicsiRNAGFPcontain-
ing PIT (pDG143; PSV40-Pip-siRNAGFP-VP16-pA) was co-transfected
with pDG213 (PPIR-TAGGFP-SEAP-pA).
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strated that only the intronic siRNA containing trans-
regulators enabled suﬃciently tight OFF expression
in which apoptosis was at the same level as that observed
in negative control transfections (Figure 6). Importantly,
maximal expression of the intronic siRNA systems was not
overly compromised as evidenced by the roughly equiva-
lent levels of apoptosis in native versus intronic siRNA
systems in their respective ON conﬁgurations.
The utility of the intronic siRNA containing systems
was further tested in CHO-K1 using the linamarase–lina-
marin prodrug system (27). In this system linamarase
expression enables conversion of the otherwise harmless
prodrug linamarin into highly toxic and readily diﬀusible
gaseous cyanide. While linamarase is only expressed intra-
cellularly, any produced gaseous cyanide can readily dif-
fuse to neighboring cells thereby resulting in highly
eﬃcient cell killing through a ‘bystander eﬀect (27)’.
Similarly to RipDD, Linamarase (Lis) was expressed
downstream of the requisite TAGGFP containing EOFF/
EON responsive promoters (EOFF pDG286; PETR1-
TAGGFP-Lis-pA and EON pDG289; PETRON1-TAGGFP-
Lis-pA) and assessed for native and intronic siRNA
containing ET1 and ET4 performance (Figure 7). As evi-
denced both by microscopic imagery (Figure 7A) and cell
viability assessment (Figure 7B), the diﬀerence between
native and intronic siRNA containing transregulation in
either OFF conﬁguration (+EM for EOFF and –EM for
EON) was highly evident. It was only by using intronic
siRNA-mediated regulation that basal expression of lina-
marase was suﬃciently abrogated to prevent high cell
death. Indeed for the EOFF system, and consistent with
results described earlier using the quantitative SEAP
reporter gene, the intronic siRNA containing system in
its OFF conﬁguration resulted in lower cell death than
equivalent experiments with the linamarase expressing
plasmid alone (Rpt. Only, Figure 7). This succinctly
demonstrated the ability of intronic siRNA to reduce
basal expression levels below that inherent to the regulable
promoter, and most critically, how this relatively small
eﬀect can equate to a major diﬀerence at a biological
process level.
Simple, one-step autoinducible siRNA vectors
To fully explore the concept of intronically encoded
siRNA within a transregulatory control system the con-
stitutive PSV40 promoter of pDG1 and pDG153 (intronic
siRNAGFP containing ET1 and tTA, respectively) were
switched for the respective cognate promoters for each
transactivator thereby generating EM- (pDG165; PETR1-
E-siRNAGFP-VP16-pA) and Tet- (pDG179; PhCMV
 
 1-
TetR-siRNAGFP-VP16-pA) responsive autoregulatory
vectors (Figure 8). In each case the respective transregu-
lator not only positively drives its own expression, but also
its intronically encoded siRNA. Addition of the respective
inducer shuts oﬀ both transactivator and siRNA expres-
sion. Signiﬁcantly, each vector contains all the necessary
elements to enable controllable siRNA expression within a
single compact format. The ET1-based vector is encoded
within 3.5kb; the tTA-based vector within 3.9kb. In
co-transfections with a GFP target (pLEGFP-N1), and
relevant to the appropriate isogenic controls (pDG164;
PETR1-E-VP16-pA, and pWW35), the autoregulated
EM-responsive system was capable of mediating GFP
silencing to almost the same degree as constitutively
expressed intronic siRNA (pDG1). Importantly, the addi-
tion of EM was suﬃcient to shut-oﬀ ET1 expression with
a consequent decrease in siRNA expression and GFP
silencing. Similarly, the Tet-responsive system was capable
of mediating strong silencing of a co-transfected GFP
TAGed reporter construct (pLM65; PhEF1a-TAGGFP-
SEAP-pA), relative to isogenic controls (pDG178;
PhCMV
 
 1-VP16-pA), which could be alleviated across a
relatively broad Tet concentration range.
A higher-fold in vitroand in vivoepigenetic toggle switch
using intronically encoded siRNA
The utility of tighter gene control systems was demon-
strated by applying the earlier concepts to improve the
performance of a synthetic gene network; in particular,
the mammalian epigenetic toggle switch (2). In its native
conﬁguration this network consists of the PIPON and EON
antibiotic-inducible transrepressor control systems
arranged such that they repress each other’s expression
(Figure 9). The system is capable of two stable expression
states depending upon which transrepressor is actively
repressing the other. Critically, and to distinguish it
from a typical on versus oﬀ gene control system,
the switch from one state to the other only requires the
transient administration of an appropriate inducer.
Co-transfection of native toggle components pBP62
(PPIRON-E-KRAB-IRES-pA) and pBP139 (PETRON1-
Pip-KRAB-IRES-SEAP-pA) into CHO cells, followed
by incubation with either EM or PI for 24h, results in
two distinct expression levels which are maintained for
the subsequent 24h after substitution with inducer-free
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Figure 6. Comparisonofconstitutive,andconditionalnativeandintronic
siRNAcontainingEOFF andEON,RIPdeathdomain(RipDD) expression
inHeLacells.Theproportionofapoptoticcells(cellspositivelystainedfor
either or both of annexin V or 7-AAD) was determined after transient
co-transfection of ET1/ET4 responsive RipDD expression constructs,
containing an siRNA target sequence (TAGGFP) immediately upstream
oftheRipDDgene(EOFFpDG289; PETR1-TAGGFP-RipDD-pA andEON
pDG290; PETRON1-TAGGFP-RipDD-pA), and the relevant native
(Nat. ET1 pWW35; PSV40-E-VP16-pA and Nat. ET4 pWW43; PSV40-
E-KRAB-pA) or intronic siRNAGFP containing (Int. ET1 pDG1;
PSV40-E-siRNAGFP-VP16-pA and Int. ET4 pDG97; PSV40-E-siRNAGFP-
KRAB-pA) transregulator, and grown for 72h in the presence or absence
of 5mg/ml erythromycin (EM). Mock-transfected cells (Ctrl.) and cells
transfected with constitutively expressed RipDD (pWW326; PhEF1a-
RipDD-pA) were used as respective controls.
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and siRNALuc [luciferase-speciﬁc siRNA (29)] placed
between each transrepressor, and targeting a siRNA-spe-
ciﬁc TAG placed immediately upstream of each opposing
transrepressor, a variant of the native toggle was engi-
neered which used both transrepression as well as gene
silencing to control expression of the opposing construct
(Figure 9A). Upon co-transfection of this network,
encoded on pDG161 (PPIRON-TAGGFP-E-siRNALuc-
KRAB-IRES-pA) and pDG168 (PETRON1-TAGLuc-Pip-
siRNAGFP-KRAB-IRES-SEAP-pA), into CHO a bistable
expression pattern also resulted which was maintained
following the withdrawal of relevant inducers
(Figure 9B). Signiﬁcantly, the use of gene-silencing
through intronically encoded siRNA increased the
dynamic range of the two stable states. The initial presence
of PI (for the ﬁrst 24h only), which induces the lower
expression state, resulted in SEAP expression levels of
0.25 and 0.47U/l after 24 and 48h, respectively, whereas
the native toggle resulted in 0.55 and 0.76U/l, respectively.
This demonstrated that intronically encoded siRNALuc
reduced Pip-KRAB and SEAP expression further than
E-KRAB-mediated repression could alone, thus eﬀectively
lowering the leakiness of the system. Conversely, in the
initial presence of EM (for the ﬁrst 24h only), the intronic
toggle yielded SEAP levels of 1.83 and 3.03U/l, and the
native toggle 1.71 and 1.51U/l, again at 24 and 48h. In
this instance, intronic siRNAGFP minimized leaky
E-KRAB expression, thus enabling higher Pip-KRAB
and SEAP expression compared to the native conﬁgura-
tion. In relation to the dynamic range, the intronic toggle
exhibited an induction factor of 7- and 6-fold, compared
to 3- and 2-fold for the native toggle at 24 and 48h,
respectively.
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Figure 7. Impact of constitutive and EOFF/EON regulated linamarase (Lis) expression, with linamarin (Lin) application, on CHO-K1 cell viability. (A)
Light microscopy (scale bar 50mM) and (B) cell viability of harvested cells after ET1/ET4 responsive Lis expression constructs containing an siRNA
target sequence (TAGGFP) immediately upstream of the Lis gene (EOFF pDG286; PETR1-TAGGFP-Lis-pA and EON pDG287; PETRON1-TAGGFP-Lis-
pA) were transfected alone (Rpt. Only) or together with the relevant native (Nat. ET1 pWW35; PSV40-E-VP16-pA and Nat. ET4 pWW43; PSV40-E-
KRAB-pA) or intronic siRNAGFP containing (Int. ET1 pDG1; PSV40-E-siRNAGFP-VP16-pA and Int. ET4 pDG97; PSV40-E-siRNAGFP-KRAB-pA)
transregulator and grown for 96h in the presence of Lin, and the presence or absence of 5mg/ml erythromycin (EM). Mock-transfected cells (Ctrl.)
and cells transfected with constitutively expressed Lis (pWW315; PhEF1a-Lis-pA), grown in either the presence or absence of Lin were used as
respective controls.
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in vivo studies we constructed a double transgenic cell
line, CHOTOGGLE2, stable for pDG161 and pDG168
(Figure 10). After an initial 3-day period to set popula-
tions to either a high or low SEAP expression state
(using EM or PI), each population was subjected to a
further 9-day incubation phase in inducer-free media
(Figure 10A). Analysis of expression levels every 3 days
showed that the diﬀerential expression state of each popu-
lation was maintained over this period. In a similar experi-
mental setup, cell populations were initially exposed to
one inducer to set expression patterns before multiple
switching of inducer regimes (Figure 10B). In each case
the cell populations exhibited full reversibility in the pre-
sence of a diﬀerent inducer thus indicating that the net-
work retained its superior bistable characteristics even
after repeated switching between states. Finally, to demo-
nstrate that the intronic toggle was also capable of impro-
ved in vivo performance CHOTOGGLE2 cells were
microencapsulated and intraperitoneally implanted into
mice. All mice were initially dosed with either PI and
EM, following which only a subset were exposed to
ongoing inducer dosing (Figure 10C). For either PI or
EM dosed mice, serum SEAP expression levels were simi-
lar regardless of whether dosing was continuous or only
transient. Secondly, the induction ratio between transient
EM versus PI dosed mice of 7- (3d), 9- (6d) and 7-fold (9d)
remained higher at all times in the intronic siRNA net-
work compared to the previously published native toggle
network (2).
DISCUSSION
Typical mammalian heterologous gene control systems
consist of a regulable promoter controlled by a constitu-
tively expressed transregulator (13). In this work an intro-
nically encoded siRNA was simultaneously co-expressed
with a functional transregulator that controlled expression
of a reporter gene that was itself targeted by the siRNA.
Signiﬁcantly, in the ON conﬁguration the ratio of siRNA
to target mRNA was lower than where the same promoter
is in the OFF conﬁguration. Computational models, refer-
enced to the molecular and biochemical parameters of
RISC-based siRNA interference processes, and experi-
mentally validated using synthetic transcription-
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Figure 8. Schematic illustration and regulation performance within CHO-K1 of autoregulated intronic siRNA systems responsive to either erythro-
mycin or tetracycline. In either system, each transactivator is under the transcriptional control of its own cognate promoter thereby providing
positive autofeedback control for not only the transactivator itself, but also the intronically encoded siRNA contained within the respective
transactivator. (A) Erythromycin responsive autoregulated siRNA in which GFP silencing was assessed after co-transfection of pLEGFP-N1
(PhCMV-GFP-pA) with either constitutively produced intronic siRNA (pDG1; PSV40-E-siRNAGFP-VP16-pA) or autoregulated intronic siRNA
(pDG165; PETR1-E-siRNAGFP-VP16-pA) in the presence or absence of 5mg/ml erythromycin (EM). In each case gene expression was assessed
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gene activity was assessed relative to pLM65 co-transfection with an isogenic (Native) non-siRNA control (pDG178; PhCMV
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rate of mRNA disappearance and eventual mRNA steady
state level are directly inﬂuenced by the relative concentra-
tions of siRNA to target mRNA (35,37). This feature was
exploited in the above conﬁguration with the resulting
diﬀerences in gene silencing used to increase the induction
window of several common gene control systems.
Signiﬁcantly, this diﬀerential silencing eﬀect was observed
across many tested mammalian cell types, and occurred
irrespective of the underlying regulable promoter thus
demonstrating the broad applicability of the approach.
Since the development of mammalian gene control sys-
tems, many strategies have focused upon improving induc-
tion characteristics by eliminating residual expression.
Given its early development and subsequent widespread
adoption much of this work has been speciﬁcally aimed
at the Tet-responsive system. Thus incremental
improvements to the original Tet conﬁguration have
been achieved by mutational enhancement of the Tet
DNA-binding domain to improve its binding and sensitiv-
ity (38–40), by modifying the Tet-cognate promoter
(41,42), and ﬁnally by combining non-heterodimerizing
reverse Tet-transactivators with antagonizing Tet-repres-
sors (43–47). While successful on their own or in combi-
nation, each of these enhancements is speciﬁc to the Tet-
system and not easily reproducible for other gene control
systems. At a more general level it is possible to alter the
properties of any gene control system through multimer-
ization and alternate spacing of operator sites, choice of
underlying promoter, as well as selection of transregula-
tory protein (41,48–51). However, the systems described to
date have generally explored these avenues and are
already optimized. An alternate, but time-consuming
and poorly scalable, avenue is to stably transfect a gene
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Figure 9. (A) Schematic depiction of an intronic siRNA-containing genetic toggle network consisting of two transpressors [pristinamcyin (PI)-
inducible Pip-KRAB and erythromycin (EM)-inducible E-KRAB] conﬁgured in a mutually oppressing manner whereby each repressor is under
the transcriptional control of the opposing repressors cognate promoter (PETRON1 and PPIRON, respectively). Each transrepressor contains an
intronically encoded siRNA [either GFP- (siRNAGFP) or Luc- (siRNALUC) speciﬁc] directed against a TAG placed immediately upstream of the
opposing transrepressor. SEAP, encoded downstream of Pip-KRAB via an internal ribosome entry site (IRES), provides a read-out of the network’s
expression status. (B) Regulation performance of the native (non-siRNA intron nor TAG containing) toggle switch (pBP62; PPIRON-E-KRAB-
IRES-pA, and pBP139; PETRON1-Pip-KRAB-IRES-SEAP-pA) versus the intronic siRNA toggle switch (pDG161 and pDG168) following transient
co-transfection in CHO-K1. In each case only a transient pulse of eﬀecter (presence indicated by shading) is required to enable the opposing
repressor to be maximally transcribed until, in a self-perpetuating manner, it stably represses the originally active promoter. Either of the two steady
states are maintained in a following removal of relevant eﬀecter molecules (non-shaded region) by substitution with fresh media.
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mance by single cell cloning (11,12). Finally, several
attempts have also been made to explicitly reduce leaki-
ness through the engineering of synthetic gene networks.
Early networks were based on transcriptional cascades of
several independently operating gene control systems
(52,53). Later attempts have built upon these networks
and sought to utilize conditional RNA interference to
actively eliminate basal reporter expression (35,54). In
some cases, however, the required number of interacting
elements and associated complexity has rendered each
system relatively user unfriendly and not readily adaptable
to new systems. In contrast a far simpler generic solution
is presented here that does not entail signiﬁcant added
complexity and which can be applied to most gene control
systems that share the same essential architecture. This
was illustrated by improving the performance characteris-
tics of three common antibiotic responsive control systems
for which the only manipulation required was the inser-
tion of an intronically encoded siRNA on the transregu-
lator and placement of a siRNA target immediately
upstream of the desired reporter gene.
By placing a transactivator containing an intronically
encoded siRNA under transcriptional control of the trans-
activator’s cognate promoter it was also possible to engi-
neer a highly eﬀective autoregulable silencing vector. This
tool enables one-step genetic engineering of eukaryotic
cells for adjustable expression of a siRNA. Signiﬁcantly,
these vectors contain all the necessary elements for self-
regulation within a single cistron on a single plasmid that
is less than 4kb in size. Over the past 5 years mammalian
gene regulation technology has been progressively applied
to siRNA expression (55–59) and indeed autoregulated
siRNA expression vectors have also been developed (58).
However, such vectors typically encode the regulatory
component (e.g. tTA) and the siRNA responsive compo-
nent as two independent cistrons, with associated promo-
ters and mRNA processing sequences, on the one plasmid.
Here, issues associated with cross-promoter competition
or interaction are circumvented, and the number of intro-
duced genetic elements minimized, by simultaneously
expressing the siRNA and regulatory component from
the same cistron. Importantly, by applying the design
using two diﬀerent systems (i.e. EOFF and TetOFF) it was
demonstrated that the architecture is also generically
applicable. Thus, it could used to create autoinducible
vectors responsive to other eﬀective molecules by simply
switching both the DNA-binding protein and cognate pro-
moter for one speciﬁc to the desired gene control system.
This technology could also easily be combined with multi-
cistronic expression technology to enable autoregulated
expression control of several siRNAs and transgenes all
oﬀ a single vector (29,60). This could be a useful tool for
the study or engineering of combinatorial eﬀects of diﬀer-
ent genes in mammalian cells.
While the generic strategy described earlier was used to
improve the induction window of several gene control
systems it did nonetheless also result in a reduction in
maximum expression levels. Arguably the most common
problem with existing mammalian gene control systems is
not with maximum expression levels, but with leaky
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Figure 10. (A) Long-term bistability of transgenic CHO-K1 cells
(CHOTOGGLE2) engineered for an intronic siRNA containing genetic
toggle network by stable transfection of pDG161 (PPIRON-TAGGFP-
E-siRNALuc-KRAB-IRES-pA) and pDG168 (PETRON1-TAGLuc-Pip-
siRNAGFP-KRAB-IRES-SEAP-pA). Two cell populations were grown
for 3 days in the presence of either pristinamycin (PI) or erythromycin
(EM) to set initial SEAP expression levels (presence of eﬀecters indi-
cated by shading). Cells were subsequently harvested, reseeded in eﬀec-
ter-free media, and assayed for SEAP activity every 3 days over a total
period of 9 days. (B) Expression reversibility in CHOTOGGLE2. Again,
two cell populations were initially grown for 3 days in the presence of
either PI or EM to set expression levels, followed by a further 3-day
cultivation in eﬀecter-free media. At days 6 and 12, eﬀecter dosing was
switched. SEAP was scored immediately prior to each media change
and at day 15. (C) In vivo expression control of microencapsulated
CHOTOGGLE2 cells implanted intraperitoneally into mice. Serum
SEAP levels were quantiﬁed at days 3, 6 and 10 for four groups of
mice which were initially exposed to 3 days of either daily PI or EM
eﬀecter injections. Eﬀecter injections were subsequently halted for two
groups of mice (3d) whereas the remaining two groups served as con-
trols in which respective eﬀecter administration was maintained daily
over the following 7 days (10d). Shown are mean values including SD
of at least six mice per timepoint.
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expression for tighter residual expression may be an accep-
table compromise that will be of signiﬁcant beneﬁt to many
applications. We have demonstrated this by using introni-
cally encoded siRNA-based regulation to conditionally
express highly biologically toxic genes such as the RipDD
and linamarase–linamarine prodrug system. Critically in
both cases, siRNA silencing of residual expression enabled
tight suppression in OFF conﬁgurations which produced
outcomes equivalent to control experiments. While siRNA
silencing alsooccurred during the respective ON conﬁgura-
tions it was not suﬃcient to unduly compromise the aﬀect
of highly potent gene products such as RipDD and lina-
marase. To further illustrate the utility of diﬀerential silen-
cing we have also utilized intronic siRNA technology to
engineer an improved epigenetic toggle that exhibits a far
greater induction window than the equivalent native (non-
intronic) version (2). This was demonstrated in not only
transiently transfected mammalian cells, but also encapsu-
lated stably transfected cells that were implanted into mice.
Signiﬁcantly, we believe that the in vivo demonstration of
the superior mammalian toggle characteristics substanti-
ates its future utility for therapeutic and other applied
usage.
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